Literature DB >> 26956132

Lipotoxicity as a trigger factor of renal disease.

Adriana Izquierdo-Lahuerta1, Cristina Martínez-García1, Gema Medina-Gómez2.   

Abstract

In the last few decades, rapid changes in lifestyle have led to an alarming increase in the prevalence of obesity and obesity-associated complications. Obese patients are at increased risk of developing hypertension, heart disease, insulin resistance, dyslipidemia, type 2 diabetes and kidney disease. The surplus of calories is normally stored as triglycerides in adipose tissue. However, excess lipids can also accumulate ectopically in other organs, including the kidney, contributing to their damage through toxic processes named lipotoxicity. The kidney is negatively affected by dyslipidemia, lipid accumulation and changes in circulating adipokines that bring about alterations in renal lipid metabolism and promote insulin resistance, generation of reactive oxygen species and endoplasmic reticulum stress, ultimately leading to alterations in the glomerular filtration barrier and renal failure. This review focuses on the pathogenic molecular mechanisms associated with renal lipotoxicity, and presents new insights about potential new therapeutic targets and biomarkers such as microRNAs and long non-coding RNAs, of relevance for the early detection of lipid-associated kidney disease.

Entities:  

Keywords:  Biomarkers; Kidney disease; Lipotoxicity; Long non-coding RNAs; miRNAs

Mesh:

Substances:

Year:  2016        PMID: 26956132     DOI: 10.1007/s40620-016-0278-5

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  68 in total

Review 1.  Lipid biology of the podocyte--new perspectives offer new opportunities.

Authors:  Alessia Fornoni; Sandra Merscher; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

2.  Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation.

Authors:  Feng Zheng; Alessia Fornoni; Sharon J Elliot; Youfei Guan; Matthew D Breyer; Liliane J Striker; Gary E Striker
Journal:  Am J Physiol Renal Physiol       Date:  2002-04

3.  Susceptibility of podocytes to palmitic acid is regulated by fatty acid oxidation and inversely depends on acetyl-CoA carboxylases 1 and 2.

Authors:  Kapil Kampe; Jonas Sieber; Jana Marina Orellana; Peter Mundel; Andreas Werner Jehle
Journal:  Am J Physiol Renal Physiol       Date:  2013-12-11

Review 4.  FFAs: do they play a role in vascular disease in the insulin resistance syndrome?

Authors:  Sudha S Shankar; Helmut O Steinberg
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

Review 5.  MicroRNAs in kidney physiology and disease.

Authors:  Piera Trionfini; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-11-11       Impact factor: 28.314

6.  Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.

Authors:  T Nakamura; C Ushiyama; S Osada; M Hara; N Shimada; H Koide
Journal:  Metabolism       Date:  2001-10       Impact factor: 8.694

7.  Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids.

Authors:  Jonas Sieber; Maja Tamara Lindenmeyer; Kapil Kampe; Kirk Nicholas Campbell; Clemens David Cohen; Helmut Hopfer; Peter Mundel; Andreas Werner Jehle
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-28

Review 8.  Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective.

Authors:  Sam Virtue; Antonio Vidal-Puig
Journal:  Biochim Biophys Acta       Date:  2010-01-06

9.  Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Yupanqui Caldas; Shinobu Miyazaki-Anzai; Hannah Santamaria; Cydney Urbanek; Nathaniel Solis; Pnina Scherzer; Linda Lewis; Frank J Gonzalez; Luciano Adorini; Mark Pruzanski; Jeffrey B Kopp; Jill W Verlander; Moshe Levi
Journal:  Diabetes       Date:  2010-08-10       Impact factor: 9.461

Review 10.  Statins in chronic kidney disease and kidney transplantation.

Authors:  Theodoros I Kassimatis; David J A Goldsmith
Journal:  Pharmacol Res       Date:  2014-07-01       Impact factor: 7.658

View more
  35 in total

Review 1.  Fibroblast growth factor 21 in chronic kidney disease.

Authors:  Paulo Giovanni de Albuquerque Suassuna; Rogério Baumgratz de Paula; Hélady Sanders-Pinheiro; Orson W Moe; Ming-Chang Hu
Journal:  J Nephrol       Date:  2018-11-14       Impact factor: 3.902

Review 2.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

3.  Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice.

Authors:  Qing-Hua Yin; Rui Zhang; Li Li; Yi-Ting Wang; Jing-Ping Liu; Jie Zhang; Lin Bai; Jing-Qiu Cheng; Ping Fu; Fang Liu
Journal:  J Biol Chem       Date:  2016-10-26       Impact factor: 5.157

4.  Knockout of Nephron ATP6AP2 Impairs Proximal Tubule Function and Prevents High-Fat Diet-Induced Obesity in Male Mice.

Authors:  Silas A Culver; Safia Akhtar; Callie Rountree-Jablin; Susanna R Keller; Helen P Cathro; John J Gildea; Helmy M Siragy
Journal:  Endocrinology       Date:  2021-12-01       Impact factor: 5.051

5.  Severe Chronic Kidney Disease Is Associated with a Lower Efficiency of Bariatric Surgery.

Authors:  Boris Hansel; Konstantinos Arapis; Diana Kadouch; Severine Ledoux; Muriel Coupaye; Simon Msika; François Vrtovsnik; Michel Marre; Anne Boutten; Blandine Cherifi; Sophie Cambos; Marie Beslay; Rodi Courie; Ronan Roussel
Journal:  Obes Surg       Date:  2019-05       Impact factor: 4.129

6.  Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.

Authors:  Hao Chiang; Jinq-Chyi Lee; Hsiu-Chen Huang; Hsing Huang; Hui-Kang Liu; Cheng Huang
Journal:  Br J Pharmacol       Date:  2019-11-12       Impact factor: 8.739

Review 7.  The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator 1α (PGC-1α) in Kidney Disease.

Authors:  Szu-Yuan Li; Katalin Susztak
Journal:  Semin Nephrol       Date:  2018-03       Impact factor: 5.299

8.  Mechanism and reversal of drug-induced nephrotoxicity on a chip.

Authors:  Aaron Cohen; Konstantinos Ioannidis; Avner Ehrlich; Shaun Regenbaum; Merav Cohen; Muneef Ayyash; Sigal Shafran Tikva; Yaakov Nahmias
Journal:  Sci Transl Med       Date:  2021-02-24       Impact factor: 17.956

Review 9.  Druggability of lipid metabolism modulation against renal fibrosis.

Authors:  Yuan-Yuan Chen; Xiao-Guang Chen; Sen Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

10.  Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism.

Authors:  Yuting Chen; Yue Dai; Kaixin Song; Yi Huang; Le Zhang; Cuntai Zhang; Qi Yan; Hongyu Gao
Journal:  Cell Death Dis       Date:  2021-06-03       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.